Dr. Jonathan Canaani discussed transplantation outcomes for acute myeloid leukemia (AML) patients at the 44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, 18–21 Mar 2018. Over the last two decades, outcomes of allo-SCT for AML patients have improved as a result of decreased NRM and improved LFS rates. The incidence of relapse has not changed.
The European LeukemiaNet (ELN) is a non-profit charitable organisation funded by donations and based on an established network of excellence where clinicians and scientists improve therapy options for leukemia patients worldwide. The ELN addresses every individual and all groups dedicated to fight leukemia - from medical doctors, researchers, healthcare professionals, patients and their relatives to private and public organisations and charities.